Emergency Medicine Hub / Toxicology & Environmental • 3 min read • 2 sections

Anticonvulsant Toxicities: Phenytoin, Carbamazepine & Valproic Acid

Comprehensive emergency evaluation and management of major anticonvulsant poisonings: phenytoin and fosphenytoin (nystagmus, ataxia, propylene glycol vehicle cardiotoxicity, extravasation purple glove syndrome), carbamazepine (anticholinergic-like sedation, QRS widening, multidose activated charcoal), and valproic acid (VPA-induced hyperammonemic encephalopathy without liver failure, cerebral edema, and intravenous L-carnitine rescue therapy).

Resuscitation Quick Actions • First 2 Minutes

High-Acuity

L-Carnitine for Valproate

100 mg/kg IV loading dose over 30 min (max 6g), then 15 mg/kg IV q4h until clinical improvement and ammonia normalizes

Phenytoin Infusion Limit

Max rate 50 mg/min IV in adults (25 mg/min elderly); must have cardiac monitor (propylene glycol causes hypotension/asystole)

Fosphenytoin Dosing

Max rate 150 mg PE/min IV; water-soluble prodrug eliminates propylene glycol vehicle cardiotoxicity and purple glove risk

Carbamazepine MDAC

Multidose Activated Charcoal (MDAC): 50g initial, then 25g q2–4h to interrupt enterohepatic recirculation

VPA Hemodialysis

Intermittent HD indicated for serum VPA > 850–1000 mg/L, refractory hyperammonemia, severe cerebral edema, or shock

Purple Glove Syndrome

Bluish-black ischemic discoloration after peripheral IV phenytoin; stop infusion, elevate limb, warm compresses, consult surgery

Bottom-Line Clinical Pearl

Phenytoin oral toxicity causes prominent neuro-vestibular findings (nystagmus at > 20 mcg/mL, ataxia at > 30 mcg/mL, lethargy/coma at > 40 mcg/mL) but minimal cardiovascular toxicity; IV phenytoin causes severe hypotension and asystole due to the propylene glycol diluent (avoid with fosphenytoin). Valproic acid overdose produces life-threatening hyperammonemic encephalopathy without marked transaminitis due to carnitine depletion and beta-oxidation inhibition; administer IV L-carnitine immediately (50–100 mg/kg IV) to reverse cerebral edema.

1. Phenytoin & Fosphenytoin Toxicity

Phenytoin blocks voltage-gated neuronal sodium channels. Oral overdoses follow non-linear Michaelis-Menten zero-order elimination kinetics: small dose increments saturate hepatic CYP2C9/CYP2C19 enzymes, resulting in dramatic, unpredictable rises in serum drug concentrations.

Serum Phenytoin Level	Dominant Clinical Presentation	Emergency Interventions
10 to 20 mcg/mL	Therapeutic Range	Monitor routine levels; no acute interventions needed.
20 to 30 mcg/mL	Horizontal gaze-evoked nystagmus, diplopia, blurred vision	Withhold doses; reassess maintenance regimen.
30 to 40 mcg/mL	Marked ataxia, dysmetria, slurred speech, tremors, nausea	Fall precautions, supportive fluids, monitor serial levels daily.
> 40 to 50+ mcg/mL	Severe lethargy, stupor, confusion, coma, paradoxical seizures	Airway protection if Glasgow Coma Scale < 8; hemodialysis is ineffective due to 90% protein binding.

Propylene Glycol Vehicle Toxicity vs. Fosphenytoin: Intravenous phenytoin requires a 40% propylene glycol and 10% ethanol solvent at pH 12 to maintain solubility. Rapid infusion (> 50 mg/min) causes profound peripheral vasodilation, bradycardia, myocardial depression, asystole, and severe tissue necrosis if extravasated (Purple Glove Syndrome). In contrast, fosphenytoin is a water-soluble prodrug that does not contain propylene glycol, can be infused three times faster (150 mg PE/min), and does not precipitate purple glove syndrome.

2. Valproic Acid & Hyperammonemic Encephalopathy

Valproate (VPA) inhibits GABA transaminase, stimulates glutamic acid decarboxylase, and blocks T-type calcium channels. In acute overdose, VPA metabolites deplete mitochondrial L-carnitine and coenzyme A, inhibiting fatty acid beta-oxidation and carbamoyl phosphate synthetase I (the first enzyme of the urea cycle). This triggers Valproate-Induced Hyperammonemic Encephalopathy (VHE) with elevated serum ammonia, cerebral edema, asterixis, and lethargy—often with completely normal liver enzymes (AST/ALT).

Therapeutic Agent	Indication in Valproate Toxicity	Dosing & Administration Route
L-Carnitine (Levocarnitine)	Symptomatic hyperammonemia (ammonia > 80–100 mcmol/L), encephalopathy, hepatotoxicity, or serum VPA > 450 mg/L	Loading dose: 100 mg/kg IV over 30 min (max 6g), followed by 15 mg/kg IV q4h until clinical recovery.
Intermittent Hemodialysis	Serum VPA > 850–1000 mg/L, severe refractory metabolic acidosis, cerebral edema, shock	Highly effective at clearing free, unbound valproic acid once protein binding sites saturate.
Meropenem (Drug Interaction)	Alternative rescue to rapidly drop serum valproic acid levels	Carbapenems irreversibly inhibit acylpeptide hydrolase and increase renal clearance, causing a 60–90% drop in serum VPA within 24 hours.

Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Anticonvulsant Toxicities: Phenytoin, Carbamazepine & Valproic Acid Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.

Related Emergency Protocols & Differentials

Related EM Protocol